23andMe Names Andy Page to Board of Directors

July 2, 2012

Mountain View, Calif. – July 2, 2012 – 23andMe, a leading personal genetics company, has announced the addition of Andy Page to its Board of Directors. “It is with great pleasure that we welcome Andy to our board,” said Anne Wojcicki, CEO and co-founder of 23andMe.”Andy’s strong finance and consumer background will be tremendously valuable as we grow the consumer genetic testing market.” Andy Page currently serves as the President of Gilt Groupe, an online luxury shopping destination, where he oversees the Company’s various businesses including Women’s, Men’s, Kids & Baby, Home, Park & Bond, Gilt City and Gilt Taste. He joined Gilt in April 2010 as the Chief Financial Officer and transitioned to President in 2011. Prior to joining Gilt, Andy was Chief Operating and Financial Officer at PlayPhone, Inc., where he was responsible for managing the company’s multinational operations. Before PlayPhone, Andy was Chief Financial Officer and SVP of Business Strategy of StubHub Inc. There he managed the company’s financial operations, business strategy, financial reporting, and administrative functions. He led the company’s sale to eBay in 2007. Andy has also held senior executive positions at Panasas Inc., ONI Systems Corp., and Robertson Stephens & Company. Andy holds a BA from Princeton University and a MBA from Harvard Business School. He is an advisor to several private e-commerce companies. He also serves on the board of directors of My New Red Shoes, a nonprofit organization that provides back-to-school clothes for homeless and low-income children in the San Francisco Bay Area.

About 23andMe

23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.